Research includes innovations in mRNA and protein engineering and delivery science to improve therapeutic propertiesย Highlights research results from ongoing collaborations with International AIDS Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID) and Bill & Melinda Gates Foundation toward development of an HIV vaccine
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 2, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new research to be highlighted at the Companyโs third annual Science Day, held virtually this year. The program is designed to provide insight into the continued diverse efforts underway at Moderna and with collaborators to better understand how to use mRNA as a medicine, and underscores the Companyโs continued commitment to basic science and innovation.โScience Day is an opportunity for us to provide insights into the advancements in our platform science and our further understanding of how to usemRNA as a medicine. Our substantial investments in basic science to date have resulted in major steps forward in our platformโs capabilities, andthese have allowed us to open new therapeutic areas and new scientific directions,โ said Stephen Hoge, M.D., President of Moderna. โToday, we’reexcited to highlight novel approaches to our lipid nanoparticle technology, which will be used with mRNA-3745, our GSD1a candidate in preclinical development. We are also pleased to provide an update on our collaboration with IAVI, NIAID and Bill & Melinda Gates Foundation toward the development of an HIV vaccine using Modernaโs mRNA platform. We remain firmly committed to further advancing our mRNA science to create a newgeneration of transformative medicines for patients.โ
